Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4822 Target Snapshot

Beta-secretase 1 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
12,221Compounds
1,210Assays
5Approved Drugs
16,693.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Beta-secretase 1 shows late clinical disease relevance led by Alzheimer disease. 2 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P56817. Start with Alzheimer disease, then reuse UniProt P56817 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Alzheimer disease, then reuse UniProt P56817 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 4 linked drugs
Open source guide
Disease program
Alzheimer disease

Beta-secretase 1 shows late clinical disease relevance led by Alzheimer disease. 2 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.

Start review with Alzheimer disease because it currently carries late clinical support. Linked drugs include ATABECESTAT, ELENBECESTAT, LANABECESTAT, VERUBECESTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 4 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Beta-secretase 1 as ChEMBL target CHEMBL4822, mapped to UniProt P56817. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Beta-secretase 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4822
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P56817
Beta-secretase 1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Beta-secretase 1 is the right protein anchor across sources, using UniProt P56817 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Alzheimer disease is currently framed as late clinical support. It currently carries 4 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameBeta-secretase 1
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP56817
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelBeta-secretase 1
UniProt AccessionP56817
Component TypeProtein
Sequence Length501 aa

Beta-secretase 1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Beta-secretase 1, mapped to UniProt P56817. Sequence length is 501 aa.

Mapped IDP56817
Review nameBeta-secretase 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Beta-secretase 1 shows late clinical disease relevance led by Alzheimer disease. 2 more disease programs remain visible in the same review block.

Late clinical Phase III
Alzheimer disease
4 linked drugs · 4 direct · 4 efficacy
Linked drugATABECESTAT
Linked drugELENBECESTAT
Linked drugLANABECESTAT
Linked drugVERUBECESTAT
Clinical signal Phase I
liver disease
1 linked drug · 1 direct · 1 efficacy
Linked drugLANABECESTAT
Clinical signal Phase I
Renal insufficiency
1 linked drug · 1 direct · 1 efficacy
Linked drugLANABECESTAT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Alzheimer disease because it currently carries late clinical support. Linked drugs include ATABECESTAT, ELENBECESTAT, LANABECESTAT, VERUBECESTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseAlzheimer disease
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

5
Approved
15
Phase III
8
Phase II
6
Phase I
Assay Mix

Activity Type Distribution

IC5013,694.0
KI2,594.0
EC50313.0
KD92.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3982593 10.96 IC50 0.011 Preclinical
CHEMBL3922902 10.85 IC50 0.014 Preclinical
CHEMBL2179131 10.77 Ki 0.017 Preclinical
CHEMBL4088234 10.62 IC50 0.024 Preclinical
CHEMBL2408786 10.51 IC50 0.031 Preclinical
CHEMBL4212046 10.48 IC50 0.033 Preclinical
CHEMBL4217023 10.47 IC50 0.034 Preclinical
CHEMBL2179138 10.44 Ki 0.036 Preclinical
CHEMBL4561849 10.05 IC50 0.09 Preclinical
CHEMBL3680900 10.0 IC50 0.1 Preclinical
Distribution

pChEMBL Value Distribution

1141
5.0
1627
5.5
1809
6.0
2174
6.5
2416
7.0
2355
7.5
1695
8.0
852
8.5
384
9.0
55
9.5
pChEMBL
Approved Drugs

Approved Drugs

DONEPEZIL
CHEMBL502
Approved 1996
Properties Compare Identifier
Assay Landscape

Assay Landscape

1,210
Total Assays
12,562
Tested Compounds
3
Assay Types
Binding — 1,206 assays, 12,562 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 752 6,599 6.8
cell-based format 347 3,206 7.0
assay format 102 2,587 6.9
cell membrane format 3 6 9.3
organism-based format 1 163 7.8
tissue-based format 1 1 7.6
Functional — 3 assays, 18 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 18 6.7
assay format 1 0 —
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine